The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
BMY Buyback image

Bristol Myers Squibb Buyback

OLI recorded this information on 12/7/2023

Company: Bristol Myers Squibb
Buyback: BMY buyback
$Amount Authorized: $5,000,000,000
Buyback Details: Bristol Myers Squibb (NYSE:BMY) today announced that on December 6, 2023, its Board of Directors authorized the repurchase of an additional $3 billion of the company's common stock under the company's multi-year share repurchase program. With this increase, the company's total outstanding share repurchase authorization is approximately $5 billion. The program enables management to execute repurchases at its discretion.

Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor T-cell therapies. Co.'s primary product includes Eliquis® - Eliquis (apixaban), which is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.

Bristol-Myers Squibb SEC Filing Email Alerts Service

Preferred: BMYMP


Open the BMY Page at The Online Investor »

BMY — Key Stats (updated Fri., Apr. 26, 10:29 AM)
Company Name:  Bristol Myers Squibb Co.
Stock buyback:  BMY buyback
Website:  www.bms.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding BMY:  125
Total Market Value Held by ETFs:  $11.71B
Total Market Capitalization:  $98.80B
% of Market Cap. Held by ETFs:  11.85%
 

Open the BMY Page at The Online Investor (in a new window) »
April 28, 2024  •  8:32 PM Eastern
BMY — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree BMY Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Hold (2.35 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts' Target Price:
BMY Stock Forecast

 Based on Zacks ABR data;
powered by Xignite

BMY Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.